-
Jan 16, 2025 | 
globenewswire.com | Avacta Plc
Meaningful tumor shrinkage observed in five out of 10 patients with partial and minor responses and 90% disease control rate in patients with salivary gland cancers Phase 1b expansion cohorts screening patients in triple negative breast cancer, soft tissue sarcoma and salivary gland cancer LONDON and PHILADELPHIA, Jan.
-
Jan 13, 2025 | 
globenewswire.com | Avacta Plc
LONDON and PHILADELPHIA, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced the appointment of Brian Hahn as Chief Financial Officer (CFO).
-
Oct 10, 2024 | 
gisweb.vwd.com | Avacta Plc
10 October Avacta Group plc ("Avacta" or "the Group" or "the Company") Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs at 2024 EORTC-NCI-AACR Symposium LONDON, UK, 10 OCT 2024, Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments, today announced that the Company will present new preclinical data on two breakthroughs in the pre|CISION(TM) platform in poster sessions at the 2024 EORTC-NCI-AACR...
-
Sep 14, 2024 | 
gisweb.vwd.com | Avacta Plc |James Steel
This announcement contains inside information for the purposes of Article 7 of
the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue
of the European Union (Withdrawal) Act 2018, as amended ("MAR"). Upon the
publication of this announcement via a Regulatory Information Service, this
inside information is now considered to be in the public domain.
-
Jul 21, 2023 | 
investing.thisismoney.co.uk | Avacta Plc |Alastair Smith |Tony Gardiner |Michael Vinegrad
RNS Number : 8454G Avacta Group PLC 21 July 2023 21 July 2023 Avacta Group plc ("Avacta" or the "Group" or the "Company") Issue of Equity and Total Voting Rights Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces it has issued and allotted a total of 3,752,652 new ordinary shares of 10 pence each in the Company ("New Ordinary Shares").
-
Jun 21, 2023 | 
business.starkvilledailynews.com | Avacta Plc
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces that the fifth dose escalation cohort in the ALS-6000-101 dose escalation Phase 1 clinical trial to evaluate the safety and tolerability of AVA6000 has been completed successfully.
-
Jun 19, 2023 | 
sharesmagazine.co.uk | Avacta Plc
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ('MAR'). Upon the publication of this announcement via Regulatory Information Service ('RIS'), this inside information is now considered to be in the public domain.
-
Apr 27, 2023 | 
markets.buffalonews.com | Avacta Plc
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the first patient has been dosed in the US under its Investigational New Drug (IND) Application in Avacta’s phase 1 multi-centre trial evaluating the safety and tolerability of AVA6000, a novel tumour targeted form of doxorubicin and Avacta’s first therapeutic product based on its proprietary pre|CISION™ technology.
-
Apr 6, 2023 | 
markets.buffalonews.com | Avacta Plc
Memorial Sloan Kettering Cancer Center and Fred Hutch Cancer Center now open for patient enrolment to pre|CISION™ lead programme, AVA6000 Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces the opening on 5 April 2023 of the first two clinical investigator sites for the phase 1 clinical trial of AVA6000 under its US Investigational New Drug (IND) Application.The two sites, Memorial Sloan Kettering Cancer...
-
Apr 5, 2023 | 
markets.buffalonews.com | Avacta Plc
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the first patient has been dosed in the fifth cohort of the first-in-human phase I trial (ALS-6000-101) of AVA6000. This follows the approval of an amended clinical trial protocol by the Medical and Healthcare Products Regulatory Agency (MHRA) to allow for higher levels of dosing.
